EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

The International Liver Congress 2019

 

10-14 April 2019 Vienna
Close
N. Poster
Poster title
Applicant name
Status
  LBP-001 In NAFLD, alcohol drinking habits and genetics predict progression to advanced liver disease: follow-up of population surveys Fredrik berg Received Received
  SAT-001 Validity of urinary bio markers and cardiac echo in diagnosis of acute kidney injury in patients with liver cirrhosis Amany Abbasy Received Received
  FRI-001 The PBC-10: A validated short clinic symptom screening tool for primary biliary cholangitis Laith Alrubaiy Received Received
  THU-002 Macrophage activation marker neopterin predicts liver transplantation-free survival in primary sclerosing cholangitis Johannes R Hov Received Received
  FRI-004 Cirrhosis status at diagnosis, non-Caucasian descent, treatment response and age determine long term survival in autoimmune hepatitis Maaike Biewenga Received Received
  THU-004 Lactobacillus rhamnosus GG prevents liver fibrosis through intestinal FXR/FGF15-mediated inhibition of bile acid synthesis and the increase of bile acid excretion in mice Wenke Feng Received Received
  SAT-004 Bacterial translocation in patients with liver cirrhosis and variceal bleeding Christos Triantos Received Received
  LBP-004 Investigation of synbiotic treatment in non alcoholic fatty liver disease (NAFLD): Results of the INSYTE study Chris Byrne Received Received
  LBP-005 classification and mutation prediction based on liver cancer hisopathological images using deep learning Mingyu Chen Received Received
  THU-005 Activation regulators of peripheral blood and intrahepatic T effector cells in autoimmune hepatitis Pamela Filpe Received Received
  FRI-005 Characteristics and outcome of autoimmune hepatitis-primary biliary cholangitis and autoimmune hepatitis-primary sclerosing cholangitis overlap patients compared to autoimmune hepatitis patients Maaike Biewenga Received Received
  SAT-005 Prognostic factors associated with mortality of acute variceal hemorrhage in cirrhotic patients : Multi-center results Kuntapon Akkarachinores Received Received
  SAT-007 Survival and risk factors of mortality after emergency transjugular intrahepatic portosystemic shunt for uncontrolled acute variceal bleeding caused by cirrhosis-related portal hypertension Manon Allaire Received Received
  THU-007 Absence of BSEP (ABCB11) protects MDR2 (ABCB4) KO mice from cholestatic liver and bile duct injury through anti-inflammatory bile acid composition and signaling Claudia Fuchs Received Received
  FRI-008 Incidence, prevalence and mortality of primary sclerosing cholangitis in Italy: A population-based study Marco Carbone Received Received
  SAT-008 Quality of medical care measurement in hepatic cirrhosis outpatients: Is there room for improvement? Alberto Amador Received Received
  SAT-009 Pharmacokinetics of ertapenem in plasma and ascitic fluid in cirrhotic patients with spontaneous bacterial peritonitis Alberto Amador Received Received
  FRI-009 Bezafibrate add-on therapy in high-risk primary biliary cholangitis is associated with prolonged predicted survival even in patients with incomplete biochemical improvements Christophe Corpechot Received Received
  FRI-010 Bezafibrate add-on therapy in high-risk primary biliary cholangitis is associated with an improvement of fibrometer and fibrometer-VCTE, two high-accuracy non-invasive fibrosis tests extensively validated in frequent chronic liver diseases Christophe Corpechot Received Received
  THU-010 Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis Alessio Gerussi Received Received
  SAT-011 Cirrhotic patients:Is there any role to malnutrition in predicting mortality? Cátia Arieira Received Received
  LBP-011 Is it possible to successfully link migrants from low-income countries to HBV, HCV, and HIV services upon arrival in the European Union? Jeffrey V Lazarus Received Received
  SAT-012 Alterations in skin microbiota, serum bile acids and autotaxin modulate itching intensity in patients with cirrhosis JASMOHAN BAJAJ Received Received
  SAT-013 Potentially Preventable readmissions and complications in hospitalized patients with hepatic encephalopathy in a large multi-center cohort JASMOHAN BAJAJ Received Received
  THU-014 Primary sclerosing cholangitis-associated biliary neoplasia demonstrates a high inter- and intratumour heterogeneity Eline Kamp Received Received
  THU-015 Mutational signatures during the neoplastic cascade towards cholangiocarcinoma in primary sclerosing cholangitis Eline Kamp Received Received
  SAT-017 Anticoagulant effect of edoxaban in patients with cirrhosis: The POET study Sarah Bos Received Received
  THU-018 c-Jun N-terminal kinases act synergistically in hepatocytes to protect mice from cholestatic liver injury Mohamed Ramadan Mohamed Received Received
  FRI-019 Readmission in hospitalized patients with autoimmune hepatitis in nationwide inpatient setting Xiaowen Fan Received Received
  FRI-020 Identification of risk factors for histological progression with sequential liver biopsies in primary cholangitis patients Yukihisa Fujinaga Received Received
  SAT-021 How to use platelets and liver stiffness to rule out esophageal varices needing treatment? Paul Cales Received Received
  FRI-022 Characteristics of autoimmune hepatitis with acute presentation Ana Gómez Received Received
  SAT-023 The lack of benefit of prophylactic transfusions of patients with cirrhosis and esophageal varices undergoing endoscopic variceal ligation Andres Cardenas Received Received
  SAT-024 Effect of acute kidney injury on long-term outcomes of spontaneous bacterial peritonitis in cirrhotics using ICA-AKI criteria Ju-Yeon Cho Received Received
  FRI-024 Incidence and prevalence of autoimmune hepatitis in England 1997-2015. A population-based cohort study Lisbet Grnbk Received Received
  FRI-025 Long-term outcome in autoimmune hepatitis: The second twenty years Laura Harrison Received Received
  SAT-026 Mid-arm circumference and triceps skinfold thickness independently predicts mortality in hospitalized patients with decompensated cirrhosis Camila Saueressig Received Received
  SAT-027 Effects of propranolol on liver- and spleen-stiffness measured by MR-Elastography in patients with cirrhosis Karen Vagner Danielsen Received Received
  LBP-027 Preliminary analysis of SuperDOT-C: A cluster randomised controlled trial of pharmacy-led versus conventional treatment for HCV positive patients receiving daily opioid substitution therapy - The Tayside sites Andrew Radley Received Received
  FRI-029 Non-alcoholic fatty liver disease and steatohepatitis in autoimmune hepatitis: important player or innocent bystander? Zachou Kalliopi Received Received
  SAT-029 Prediction of hepatic hydrothorax in cirrhosis patients with ascites Thomas Deleuran Received Received
  SAT-030 Annual contrast-enhanced MRI is highly effective in the surveillance of hepatocellular carcinoma in cirrhotic patients Coskun Ozer Demirtas Received Received
  FRI-031 Association between serum immunoglobulin G levels and intrahepatic plasmacytic gene signature in human autoimmune hepatitis Atsumasa Komori Received Received
  SAT-031 Bleeding risk-scores for prediction of acute variceal bleeding outcome marwa Elfayoumy Received Received
  THU-032 Peritoneal CD206 links macrophage heterogeneity in decompensated cirrhosis with outcome of spontaneous bacterial peritonitis Tony Bruns Received Received
  SAT-034 The psychomotor vigilance task: Role in the diagnosis of hepatic encephalopathy and relationship with driving ability Chiara Formentin Received Received
  LBP-035 Kupffer cell development: A link between Notch signaling and LXRa Wouter TJonck Received Received
  SAT-035 The negative impact of skeletal muscle volume loss during transarterial chemoembolization for hepatocellular carcinoma Masashi Fujita Received Received
  THU-035 A shorter period of a subsequent episode of acute decompensation of cirrhosis predicts worse outcome: A single center experience Po-Sung Chu Received Received
  SAT-037 Applying the new nutritional screening and assessment algorithm to estimate malnutrition prevalence in Greek cirrhotic patients as suggested by the 2018 EASL nutritional guidelines for chronic liver disease Maria Vasiliki Papageorgiou Received Received
  LBP-038 Increasing Number of Metabolic Co-Morbidities are Associated with Higher Risk of Advanced Fibrosis in Patients with Nonalcoholic Steatohepatitis Robert Wong Received Received
  THU-041 Immune-metabolism disorder in progression of hepatitis B virus-related acute-on-chronic liver failure characterized by transcriptomics Jun Li Received Received
  THU-043 Declining mortality of cirrhotic patients requiring admission to intensive care units for serious infections: A bi-national cohort study Ammar Majeed Received Received
  SAT-044 Serum Myostatin in liver cirrhosis: A marker beyond malnutrition Rewan Hanno Received Received
  SAT-045 Prevalence, type and risk factors of colonization by multidrug-resistant bacteria in a large series of patients with decompensated cirrhosis Maria Hernandez-Tejero Received Received
  SAT-046 Clinical impact of rectal colonization by multidrug-resistant bacteria in patients with decompensated cirrhosis Maria Hernandez-Tejero Received Received
  THU-047 Recalbration of the CLIF-C ACLF score after weighting by organ and by the presence of TIPS in patients with acute-on-chronic liver failure Enric Reverter Received Received
  SAT-047 Easy surveillance method without need of special equipment for muscle volume loss in patients with chronic liver disease Atsushi Hiraoka Received Received
  THU-048 Intermittent high-flux albumin dialysis with continuous venovenous hemodialysis for acute-on-chronic liver failure and acute kidney injury Jacek Rozga Received Received
  FRI-049 Real world experience of obeticholic acid (Ocaliva) for the treatment of primary biliary cholangitis in the secondary care setting Anthony Pratt Received Received
  THU-049 Impaired adaptive immunity is an early event in liver cirrhosis preceding acute-on-chronic liver failure Sabrina Rueschenbaum Received Received
  SAT-050 Silymarins significantly improve long term survival in patients with liver cirrhosis regardless of MELD score Chien-Hao Huang Received Received
  SAT-051 The effects of portal vein thrombosis to patients with cirrhotic variceal bleeding underwent endoscopic treatment XIAOQUAN HUANG Received Received
  FRI-052 Long-term bezafibrate therapy does not prevent the progression of primary biliary cholangitis in patients with advanced disease Anna Reig Received Received
  SAT-052 Right psoas muscle area: Prognostic factor in patients with cirrhosis Child Pugh class C included on the waiting list for liver transplantation Speranta Iacob Received Received
  FRI-053 Overlap of primary biliary cholangitis and autoimmune hepatitis. Natural history and prognosis in a large cohort of patients from Spain Anna Reig Received Received
  SAT-054 A higher prevalence of colorectal adenomatous polyps in patients with liver cirrhosis compared with non-cirrhotics Mohamed Saleh Ismail Received Received
  THU-056 Artificial liver support system improves short-term survival of patients with hepatitis B virus-related acute-on-chronic liver failure: A propensity-score matched analysis Jun Li Received Received
  SAT-056 Development of a novel prognostic model for cirrhotic patients with difficult-to-treat ascites and low MELD scores Peter Jepsen Received Received
  FRI-057 A review of primary biliary cholangitis practice in Wales: Time for specialist care Lavanya Shenbagaraj Received Received
  SAT-057 Proton pump inhibitors as a risk factor for hepatic encephalopathy and infections in cirrhotic patients: A clinical evidence Mafalda João Received Received
  THU-058 Gene profiling of toll-like recepter signaling pathways in patients with acute-on-chronic liver failure Ruihong Zhao Received Received
  SAT-059 Prevalence and clinical characteristics of malnutrition in cirrhosis according to new EASL practice guidelines Daewon Jun Received Received
  THU-062 Exploring the immune environment in chronic hepatitis C associated fibrosis by examining the portal vein Rabab Oun Ali Anwar Ali Received Received
  SAT-063 Third-generation cephalosporins are still useful as the empirical antibiotics for spontaneous bacterial peritonitis in Korea Sun Woong Kim Received Received
  THU-064 Identification of new epigenetic targets in hepatic fibrosis Marina Barcena-Varela Received Received
  FRI-064 Systematic review and meta-analysis of risk factors for recurrent primary sclerosing cholangitis Iris Steenstraten Received Received
  SAT-065 Shear wave elastography for skeletal muscle: A novel approach to insulin resistance in cirrhosis Kazufumi Kobayashi Received Received
  SAT-066 Modified SAE tecnique provides a long last sustained hemodynamic response on splenic artery blood velocity in patients with cirrhosis and clinically significant portal hypertension Sergii Kozlov Received Received
  FRI-066 Rituximab therapy is effective for inducing remission in IgG4-RD hepatobiliary disease: A retrospective case series Danielle T Vannan Received Received
  FRI-067 Management of primary biliary cholangitis in the pre-obeticholic acid era, and the rate of non-response to ursodeoxycholic acid (UDCA), in a large real-world cohort of PBC patients in Italy: The CLEO-AIGO database Umberto Vespasiani-Gentilucci Received Received
  FRI-068 Quantitative biliary tree imaging by MRI: Evaluating new technology across patient cohorts with autoimmune liver disease gary woodward Received Received
  SAT-068 Presence of liver cirrhosis is the strongest negative predictor of survival for patients admitted to intensive care unit Alica Kubesch Received Received
  SAT-069 Interleukin 6: A marker for hepatic encephalopathy Christian Labenz Received Received
  FRI-069 Quantitative MRCP imaging: Preliminary observations in a cohort of paediatric patients with liver and biliary diseases gary woodward Received Received
  THU-069 Human adipose derived stem cells exhibit enhanced liver regeneration in liver fibrosis model by controlled releasing hepatocyte growth factor Ja Sung Choi Received Received
  FRI-070 Long-term clinical outcomes in patients with autoimmune hepatitis according to treatment response in Asian country Sun Yoo Received Received
  THU-070 The nuclear factor TCF20 regulates the severity of liver fibrosis in mice Bernat Cordoba-Jover Received Received
  THU-071 Matrix modulation in chronic liver injury and resolution Marika Crescenzi Received Received
  THU-073 The use of APRI and FIB-4 scores versus transient elastography for the assessment of liver fibrosis stage in patients with chronic hepatitis C: Is it possible to reduce the need for elastography? Melanie Deutsch Received Received
  SAT-073 Micronutrient deficiencies in patients with decompensated cirrhosis Gemma Llibre Nieto Received Received
  SAT-074 Prevalence and risk factors of colonization by multidrug resistant bacteria in cirrhotic patients admitted to the intensive care unit in a Spanish tertiary hospital Sara Lorente Received Received
  FRI-078 Serious liver injury induced by nimesulide: An international collaboration reporting 57 cases Fernando Bessone Received Received
  THU-078 PBI-4050 inhibits hepatic stellate cell activation, restores autophagy, and reduces CCl4-induced liver fibrosis Brigitte Grouix Received Received
  SAT-079 Respiratory infection in patients with cirrhosis and acute variceal bleeding on antibiotic prophylaxis: A multicenter observational study of 2138 patients Javier Martinez Received Received
  FRI-079 HLA B14:01 is associated with Trimethoprim-sulfamethoxazole induced liver injury Naga Chalasani Received Received
  FRI-081 Characterisation of severe liver injury induced by immune checkpoint inhibitors Yana Davidov Received Received
  THU-081 Saracatinib, a Src family kinase inhibitor, decreases liver fibrosis Byoung Kuk Jang Received Received
  THU-082 Thymosin beta 4 is a potential regulator of radiation-induced liver fibrosis Jieun Kim Received Received
  SAT-085 Selective improvement by rifaximin of changes in the inmunophenotype in patients who improve minimal hepatic encephalopathy Carmina Montoliu Received Received
  FRI-086 Stem cell treatment on acute liver failure model using semipermeable Poly Lactic-co-Glycolic Acid membrane pouch Bo-Kyeong Kang Received Received
  SAT-086 Opioid use is common among non-surgical inpatients with cirrhosis and is associated with increased length of stay and persistent use post-discharge Andrew Moon Received Received
  SAT-088 Sarcopenia and Myosteatosis are associated with minimal and overt hepatic encephalopathy in patients with liver cirrhosis SILVIA NARDELLI Received Received
  THU-090 Non-invasive fibrosis scores (APRI, FIB4 index, BARD): Useful tools for evaluating fatty liver disease Alina Popescu Received Received
  SAT-090 Location of onset of acute kidney injury in cirrhosis affects survival Janardhan Navaratnam Received Received
  THU-091 Acalcemic vitamin D analogues show antifibrotic effects in vitro while paricalcitol prevents progression of established fibrosis in the CCl4 mouse-model Florian Reiter Received Received
  FRI-091 HGF protector effect in intrahepatic cholestasis Elsy Soraya Salas Silva Received Received
  FRI-092 Metamizole as a leading cause of drug-induced liver injury Marcial Sebode Received Received
  SAT-092 The efficacy and safety of rifaximin-a: a 2-year observational study of overt hepatic encephalopathy Rosalie Oey Received Received
  SAT-093 Underutilization of hospice in inpatients with cirrhosis: The NACSELD experience Jacqueline OLeary Received Received
  FRI-094 Targeting NEDDylation protects liver from acute drug-induced damage Simón Jorge Received Received
  THU-094 Simple prediction score to predict fibrosis in type 2 diabetes mellitus patients Ioan Sporea Received Received
  SAT-094 Effects of branched-chain amino acids on the progression of advanced liver disease: A Korean nationwide, multicenter, prospective, observational, cohort study Jung Gil Park Received Received
  FRI-095 The overweight role in the occurrence of hepatotoxic reactions during chemotherapy of chronic lymphocytic leukaemia Igor Skrypnyk Received Received
  THU-095 Short and long-term evaluation of liver fibrosis and outcomes in patients with chronic hepatitis C after INF-free antiviral treatment Cristina Stasi Received Received
  THU-096 Development and validation of true serum biomarkers of liver fibrogenesis ans fibrolysis Rambabu Surabattula Received Received
  FRI-096 Technetium-99m-GSA within the first 3d after admission as an early predictor of outcome in severe acute liver injury Yuji Suzuki Received Received
  SAT-097 Non-invasive estimation of intravascular volume status in cirrhosis by dynamic size and collapsibility Indices of the inferior vena cava using bedside echocardiography Madhumita Premkumar Received Received
  THU-099 Collagen is not just collagen: Differential matrix expression induced by TgF-beta and PDGFs Ida Villesen Received Received
  THU-100 FGL2 regulates liverfibrosis progression and reversal by promoting profibrotic infiltrating macrophages maintenance Xiaoyang Wan Received Received
  FRI-101 FGL2 deficiency resists viral fulminant hepatitis through abrogating inflammatory macrophage activation Xiaoyang Wan Received Received
  SAT-102 Cirrhotic patients with vitamin d deficiency fail to respond to oral replacement therapy Freya Rhodes Received Received
  SAT-103 Bone disease does not correlate with severity of liver disease in cirrhosis Freya Rhodes Received Received
  FRI-106 Combining endozepine-4 and blood ammonia: Does it improve the diagnosis of hepatic encephalopathy in patients with liver cirrhosis? Mohamed Abaza Received Received
  SAT-106 Prevalence and survival of fungal peritonitis in decompensated cirrhosis Noam Roth Received Received
  FRI-107 Emerging role of taurine conjugated bile acids in the gut liver axis and on hepatic bile acid receptors in chronic hepatitis C Rabab Oun Ali Anwar Ali Received Received
  FRI-111 Albumin modulates endosomal TLR9 signaling in human peripheral leukocytes: A mechanism for its anti-inflammatory role in ACLF Mireia Casulleras Received Received
  THU-111 High efficacy and safety of the combination HCV regimen elbasvir and grazoprevir for 8 weeks in treatment-naive non-severe fibrosis HCVGT1b-infected patients: Final results of the STREAGER study Frederic Faure Received Received
  FRI-112 Prediction of treatment failures in a multicentre feasibility trial using human albumin solution to prevent infection in acute decompensation of liver cirrhosis Louise China Received Received
  FRI-113 Matrix stiffness modulates the phenotype of hepatic cells in cirrhosis and modifies the sinusoidal effects of statins Sergi Guixé-Muntet Received Received
  THU-115 Effects of health-related quality of life of interferon-free antiviral therapy for chronic hepatitis C infection - Results from the GermanhHepatitis C-Registry (DHC-R) Yvonne Serfert Received Received
  SAT-116 Development and validation of a novel model for outcome in patients with cirrhosis and acute variceal bleeding Dr Shalimar Received Received
  THU-116 Effectiveness of the salvage therapy sofosbuvir-velpatasvir-voxilaprevir (SOF-VEL-VOX) in chronic hepatitis C: Clinical practice experience from the TRIO Network NICOLE WICK Received Received
  FRI-118 Decreased cognitive performance is associated with reduced resting state connectivity and gray matter atrophy in patients with minimal hepatic encephalopathy Carmina Montoliu Received Received
  SAT-118 Estimating proportion of cirrhosis and hepatocellular carcinoma attributable to hepatitis B and C in clinical centres in Sofia (Bulgaria) and Lisbon (Portugal): Results from a European pilot Marieta Simonova Received Received
  THU-119 Direct-acting antiviral regimens without protease inhibitors may help maintain a healthy lipid profile after hepatitis C eradication Javier Fuentes Received Received
  FRI-120 Structural liver disease rather than portal hypertension is the predominant factor for hepatic macrophage activation in patients with cirrhosis, portal vein thrombosis and idiopathic portal hypertension Nikolaj Worm rntoft Received Received
  THU-120 Hepatitis C In children: Clinical profile and outcomes In the era of directly-acting antivirals in a tertiary centre in North India Vybhav Gummadi Received Received
  FRI-121 Portal hypertension in nodular regenerative hyperplasia is caused by vascular remodeling with extensive regression of portal vein branches Christian Perez Shibayama Received Received
  SAT-122 Cirrhotic cardiomyopathy: An observational study pre-liver transplant Mohsan Subhani Received Received
  SAT-123 Serum Mac-2 binding protein glycosylation isomer and handgrip strength correlate with serum myostatin level in chronic liver disease Tomoyuki Suehiro Received Received
  THU-124 Efficacy and safety of glecaprevir/pibrentasvir for the pangenotypic treatment of chronic hepatitis C in former intravenous drug users: Subanalysis from a Spanish real-world cohort (Hepa-C) Jose A. Carrión Received Received
  FRI-125 The phase angle determined by bioelectrical impedance is a predictive factor of hospitalization, falls and mortality in patients with cirrhosis Eva Roman Received Received
  SAT-125 Animal naming test is simple and reliable for diagnosis of minimal hepatic encephalopathy and prediction of development of overt hepatic encephalopathy in patients with cirrhosis Sunil Taneja Received Received
  SAT-126 Minimal hepatic encephalopathy: Proper diagnosis for a better quality of life Vlad Taru Received Received
  FRI-127 Measuring dynamics of portal pressure and vital parameters in conscious rats using real-time telemetry Philipp Knigshofer Received Received
  THU-127 Clinical Practice experience with pan genotypic therapies glecaprevir-pibrentasvir and sofosbuvir-velpatasvir in the TRIO Network NICOLE WICK Received Received
  THU-128 Renal safety in 3,264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study Roberta DAmbrosio Received Received
  THU-131 Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: A real-life study from the NAVIGATORE Lombardia and Veneto Networks Elisabetta Degasperi Received Received
  FRI-131 Impact of HBsAg level on cellular immune responses in HBeAg negative patients with chronic hepatitis B virus infection Elmira Aliabadi Received Received
  SAT-134 Hypercoagulopathy risk factors in liver cirrhosis due to non-alcoholic steatohepatitis and clinical manifestations of hypercoagulation during 5 years Nataliya Virstyuk Received Received
  THU-134 Clinical and virological characteristics of patients with chronic hepatitis C and failure to voxilaprevir/velpatasvir/sofosbuvir treatment Julia Dietz Received Received
  THU-135 Real-world HCV treatment in HCV-HIV coinfected population: Data from the TRIO network NICOLE WICK Received Received
  FRI-135 Toll-like receptor signalling induces changes in the Hippo signalling pathway that counter regulates innate immune responses in hepatocytes Ruth Broering Received Received
  FRI-136 Hepatitis B core antibody (anti-HBc) mirrors activation of hepatitis B virus-specific immune responses and exhibits direct effect on hepatitis B virus control Chengcong Chen Received Received
  FRI-137 l-carnitine impedes hepatitis B surface antigen loss through immunosuppressive effect in chronic hepatitis B virus infection Shuqin Gu Received Received
  SAT-137 Adverse drug reactions in patients with cirrhosis: analysis of spontaneous reports from the Dutch Pharmacovigilance Centre Lareb Rianne Weersink Received Received
  FRI-138 HBVcore- versus HBVpolymerase-specific CD8 T cells differ in chronically HBV-infected patients Kathrin Heim Received Received
  SAT-139 Predictive factors for the development of acute-on-chronic liver failure in a North American cohort of hospitalized patients with cirrhosis and decompensation Florence Wong Received Received
  THU-139 Real world experience of chronic hepatitis C retreatment with genotype specific regimens in non-responders to previous interferon-free therapy Robert Flisiak Received Received
  THU-140 Characteristics of patients and effectiveness of chronic hepatitis C treatment during the initial 4 years of access to interferon-free therapy Robert Flisiak Received Received
  SAT-140 The natural history of stages 2 and 3 acute kidney injury in hospitalized patients with decompensated cirrhosis and ascites Florence Wong Received Received
  FRI-140 Chemokine (C-X-C motif) ligand 13-mediated recruitment of intrahepatic chemokine (C-X-C motif) receptor 5CD8 t cells contribute to viral control in chronic hepatitis B patients and hepatitis B virus mouse model Yongyin Li Received Received
  FRI-141 Rapid decrease in titer and breath of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved sustained virological response Isidoro Martínez Received Received
  SAT-142 Incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: A territory-wide cohort study Vincent Wai-Sun Wong Received Received
  FRI-146 Long-term nucleos(t)ide-analogue treatment in chronic hepatitis B eAg(-) together with a low level of HBsAg leads to a non-exhausted HBV-specific T CD8 response Julia Peña Asensio Received Received
  THU-146 LDV/SOF/RBV is an effective first-line DAA regimen as well as re-treatment option for RF1_2k/1b patients within Georgian national hepatitis C elimination program Marika Karchava Received Received
  FRI-147 Gradual restoration of HCV-specific CD8 T cell frequency but persistence of altered phenotype in cirrhotic HCV-infected patients after successful direct-acting antiviral therapy Elena Perpiñán Received Received
  THU-147 Improvement of neutrophil function in hepatitis C patients under direct acting anti-viral treatment is associated with hemolysis parameters Irina Komarova Received Received
  SAT-147 Interaction between renal and liver impairment on the risk of lactic acidosis in diabetic patients with chronic hepatitis B-related cirrhosis Terry CF Yip Received Received
  SAT-148 The role of kidney biomarkers in cirrhotic patients with acute kidney injury: interim analysis of multicenter, prospective cohort study Jeong-Ju Yoo Received Received
  THU-148 Variability of ed extracellular matrix proteins concentrations in HCV infected patients treated with sofosbuvir and ledipasvir Krzysztof Tomasiewicz Received Received
  SAT-149 Optimal ion of sedative drug during endoscopy in cirrhotic patients to avoid minimal encephalopathy Jeong-Ju Yoo Received Received
  THU-150 Factors associated with treatment failure with SOFRBV in patients with genotype 2 chronic hepatitis C and consideration of retreatment with GLEPIB in patients not responding to SOFRBV Atsunori Kusakabe Received Received
  SAT-150 Validation of Korean stroop test in the screening of minimal hepatic encephalopathy Eileen Yoon Received Received
  FRI-151 Characterization of regulatory T cells and the role of PD-1 and TNF-alpha in spontaneous hepatitis B surface antigen seroclearance in chronic hepatitis B Fen Liu Received Received
  THU-153 Is sofosbuvir-based regimen safe and effective in hepatitis C virus-infected patients with stage 4-5 chronic kidney disease? A systematic review and meta-analysis Mingshu Li Received Received
  FRI-153 Potent hepatitis B core-specific B cell responses associate with clinical parameters in untreated and virally suppressed chronic HBV patients Thomas Vanwolleghem Received Received
  THU-157 Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection Marianne Martinello Received Received
  THU-158 High efficacy of sofosbuvir and velpatasvir regardless of patients clinical characteristics Vitor Hugo Martins Received Received
  THU-159 Real-world efficacy of elvasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group Toshie Mashiba Received Received
  FRI-159 Can HBcrAg and pre-genomic HBV RNA predict the risk of ALT flares after nucleoside analogue therapy withdrawal: delineating the clinical utility of new biomarkers? Ivana Carey Received Received
  THU-160 Outcomes of the national strategy on hepatitis C treatment with direct acting antivirals in a real-life setting: Results from a national survey in Slovenia Jerneja Videcnik Zorman Received Received
  THU-161 Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C treated with DAAs: Results from the German hepatitis C registry (DHC-R) Yvonne Serfert Received Received
  THU-162 The combination of sofosbuvir and daclatasvir is well tolerated and extremely effective in treating patients with hepatitis C with severe renal impairment including hemodialysis patinets Shahin Merat Received Received
  THU-163 Efficacy and safety of direct-acting antivirals for hepatitis C in elderly patients: a systematic review and meta-analysis Marcus Maximilian Mcke Received Received
  FRI-164 Prognostic value of various liver scoring systems in cirrhotic chronic hepatitis B patients with and without tenofovir disoproxil fumarate treatment Jonggi Choi Received Received
  FRI-165 No detectable resistance to tenofovir in patients with Adefovir- and Entecavir-resistant chronic hepatitis B after 240 weeks of treatment with tenofovir disoproxil fumarate monotherapy Jonggi Choi Received Received
  FRI-167 Effectiveness and safety with tenofovir alafenamide (TAF) for hepatitis B in US clinical practice NICOLE WICK Received Received
  THU-168 Real-life effectivness and safety of glecaprevir/pibrentasvir in HCV infected patients with chronic kidney disease Andrea Aglitti Received Received
  FRI-171 A phase 1 single ascending dose study of the safety, tolerability and pharmacokinetics of CRV431 Jill Greytok Received Received
  SAT-172 Novel mathematical modeling of HBsAg kinetics during long-term antiviral treatment: A pilot study Hwi Young Kim Received Received
  FRI-172 Outcomes of response guided therapy with pegylated interferon alpha 2a in chronic hepatitis B and D George Sebastian Gherlan Received Received
  THU-173 Sofosbuvir based anti-HCV therapy: Safe in hemodialysis Adnan Salim Received Received
  SAT-174 Formation of the occult chronic hepatitis B during antiviral therapy in patients with HIVHBVHDVHCV infection: Clinical cases Vitalii Sukachev Received Received
  FRI-175 Frequency,severity and impact of Peg-IFNa-associated flares in HDV infection: Results from the HIDIT-II study Svenja Hardtke Received Received
  THU-175 Eligibility and feasibility of hepatitis C treatment in the era of direct-acting antiviral agents: Our experience in real-world practice Monica Schiavini Received Received
  THU-176 Weight gain after interferon-free clearance of chronic hepatitis C: Results from the German hepatitis C registry (DHC-R) Yvonne Serfert Received Received
  SAT-176 The effect of HBV and HCV infection on pregnancy status Tadeusz, Wojciech Lapinski Received Received
  SAT-177 Loss of HBsAg by patients with high levels of HBV-DNA during treatment with nucleoside or nucleotide analogues Tadeusz, Wojciech Lapinski Received Received
  FRI-179 Antiviral therapy might not be required for chronic hepatitis B patients in the immune-tolerant phase with a significantly low incidence rate of liver-related events Mi Young Jeon Received Received
  THU-179 Never too old to be direct acting antiviral treated for hepatitis C virus David Mackie Received Received
  SAT-181 Efficacy and safety of glecaprevir/pibrentasvir in patients with severe renal impairment in Japan: A prospective, multicenter study (KTK 49 Liver Study Group) Masanori Atsukawa Received Received
  FRI-181 Efficacy and safety of switching therapy from tenofovir disoproxil fumarate to tenofovir alafenamide for hepatitis B virus infection Shun Kaneko Received Received
  THU-183 Prospective multicenter study of glecaprevir plus pibrentasvir combination therapy for patients with chronic hepatitis C Akihiro Tamori Received Received
  SAT-185 Is the performance of ultra-sensitive HBsAg Fujirebio assay consistent across HBV genotypes (comparison between CLEIA HBsAg HQ Fujirebio and Abbott Architect assays) Christiana Moigboi Received Received
  FRI-185 Virological and immunological predictors of long-term ouctomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B I-Cheng Lee Received Received
  THU-185 Effectiveness and safety of DAA-based treatment of hepatitis C patients with severe and end stage chronic kidney diseases - EpiTer-2 database analysis Krzysztof Tomasiewicz Received Received
  SAT-187 characterization of hepatitis e infection in israel: identification of HEV-7 in camels and high seroprevalence in specific human populations Orna Mor Received Received
  THU-187 Objective evidence of neurocognitive impairment associated with hepatitis C virus infection and of its regression after viral clearance with direct antivirals Gloria Vaghi Received Received
  SAT-189 GCAC1809-1812TTCT a novel viral quadruple mutation is strongly associated with basal core promotor double mutation and viral load in Hepatitis B e antigen negative chronic hepatitis B virus infected patients Kai-Henrik Peiffer Received Received
  THU-189 Role of comorbidites in sofosbuvir-based treatment response: Clinical experience from an Italian real life cohort Giulia Verzon Received Received
  FRI-191 EDP-514, a novel HBV core inhibitor with potent antiviral activity both in vitro and in vivo Kai Lin Received Received
  FRI-192 Tenofovir disoproxil fumarate treatment in chronic hepatitis B patients with cirrhosis reduces hepatic decompensation, hepatocellular carcinoma and death Ken Liu Received Received
  FRI-193 Long-term renal and bone safety of tenofovir disoproxil fumarate in chronic hepatitis B patients with cirrhosis Ken Liu Received Received
  SAT-193 Evolutionary relationship among hepatitis B virus genotype D in Latin America and Europe João Renato Rebello Pinho Received Received
  THU-193 4 week treatment for hepatitis C: A randomized controlled trial (4RIBC) Lone Wulff Madsen Received Received
  FRI-194 The novel antiviral agent inarigivir inhibits both nucleos(t)ide analogue and capsid assembly inhibitor resistant HBV in vitro Stephen Locarnini Received Received
  FRI-195 Long-term effect of nucleos(t)ide analogs on hepatitis B surface antigen in chronic hepatitis B patients Kenichi Morikawa Received Received
  THU-195 An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for naive chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resitance-associated substitution Ming-Lung Yu Received Received
  THU-196 Efficacy of 8 versus 12-weeks treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-weeks regimen in real world setting Dorota Zarebska-Michaluk Received Received
  FRI-196 The development of HCC in chronic hepatitis B patients with nucleos(t)ide analogs: Focus on hepatitis B surface antigen and core-related antigen Itaru Ozeki Received Received
  THU-197 Comparative effectiveness of 8 versus 12 weeks of ombitasvir/paritaprevir/ritonavir and dasabuvir in treatment-naive patients infected with HCV genotype 1b with non-advanced hepatic fibrosis Dorota Zarebska-Michaluk Received Received
  FRI-197 Prediction of elastographic reversion of cirrhosis after 5 years of entecavir or tenofovir disoproxil fumarate therapy in caucasian chronic hepatitis B patients George Papatheodoridis Received Received
  SAT-197 Quality of life measurement using wrist actigraphy in HCV genotype 1 infected, treatment nave patients suffering from fatigue and receiving ombitasvir, paritaprevir, and ritonavir tablets and dasabuvir tablets (Viekirax/Exviera; 3D regimen) David Semela Received Received
  SAT-198 Full-length 5RACE analysis discriminates all major intracellular and extracellular viral RNAs during the course of infection Bernd Stadelmayer Received Received
  SAT-199 Recombinant hepatitis E viruses harbouring tags in the ORF1 protein allow visualisation of the viral replicase Dagmara Szkolnicka Received Received
  FRI-200 Spend less get more;cost effectiveness of various models of care in hepatitis C treatment JEYAMANI RAMACHANDRAN Received Received
  SAT-201 Alternation of lipid metabolism and dysfunction of mitochondria might contribute to HCC development in the absence of overt necroinflammation Jaw-Ching Wu Received Received
  FRI-204 ASPP2: A potential strategy to inhibit HBV replication through reducing hepatocytes autophagy Ying Shi Received Received
  SAT-205 Associated risk factors for hepatitis E seroprevalence among liver transplant recipients Petra Dinjar Kujundi&263; Received Received
  SAT-206 The impact of hepatitis E virus infection on the Scottish solid organ transplant population Mhairi Donnelly Received Received
  FRI-206 Relationship between hepatitis B core related antigen levels and sustained HBeAg seroconversion in patients treated with nucleos(t)ide analogues Milan Sonneveld Received Received
  THU-208 Characterization of a novel chemiluminescent enzyme immunoassay for the quantitation of antibodies to hepatitis B core antigen class IgG and correlation with intrahepatic HBV covalently-closed-circular DNA Gian Paolo Caviglia Received Received
  THU-209 Dynamics of a transient elastography-based risk prediction model for hepatocellular carcinoma treated with antiviral therapy in chronic hepatitis B: A multi-center retrospective cohort study from the Korean Transient Elastography Study Group Hye Yeon Chon Received Received
  SAT-209 Role of estrogen and its receptors in HEV associated feto-maternal outcomes Premashis Kar Received Received
  FRI-209 Exploring TH1/TH2 adjuvants to improve the efficacy of the therapeutic vaccination against chronic hepatitis B Jinpeng Su Received Received
  FRI-210 Establishment of high rates of functional cure of HBeAg negative chronic HBV infection with REP 2139-Mg based combination therapy: Ongoing follow-up results from the REP 401 study Andrew Vaillant Received Received
  SAT-210 Circulation of hepatitis a genotypes in Israel 2017-2018: Environmental surveillance supports clinical findings Orna Mor Received Received
  FRI-211 Evaluation of the safety and tolerability of transaminase flares during antiviral therapy in patients with HBeAg negative chronic HBV infection or HBV/HDV co-infection Andrew Vaillant Received Received
  THU-212 Reactivation of occult HBV infection in HIV treated for HCV: A retrospective study Bianca Granozzi Received Received
  SAT-213 Hepatitis E virus prevalence in Flemish blood donors Ann-Sofie Vercouter Received Received
  FRI-213 HBV RNA at 6 months predicts HBeAg loss in nucleos(t)ide analogue treated HBeAg positive patients: Demonstration of clinical utility? Bo Wang Received Received
  THU-214 Annual average of integral FIB-4 index and HBV core-related antigen as an appropriate indicators for starting nucleoside analogues at an optimum timing Shuhei Hige Received Received
  FRI-214 Novel hepatitis B virus X gene mutants emerge during antiviral therapy to increase covalently closed circular DNA accumulation conferring pseudo-drug-resistance and increaing hepatocellular carcinoma risk Chau-Ting Yeh Received Received
  SAT-217 Effectiveness and safety of sofosbuvir-based regimens in treatment of chronic HCV patients aged 60 years and older, egyptian single center experience Shereen Abdel Alem Received Received
  FRI-218 Dynamic changes of serum hbv pgrna levels in patients with chronic hepatitis B treated with entecavir or peg-interferon XIAOQI YU Received Received
  SAT-218 Impact of sofosbuvir-based therapy on renal functions indices in chronic hepatitis c patients who achieved sustained virological response Reham Abdelmoniem Received Received
  SAT-219 Effect of treatment of hepatitis C by directly acting antivirals on chronic hepatitis C and B co-infected patients Ayman Sadek Received Received
  SAT-220 Higher frequency of occult HCV infection in HIV/HCV coinfected patients with advanced liver disease: Post DAAs treatment observation Sabrina Bagaglio Received Received
  SAT-221 Autoantibodies to apolipoprotein A1 (apoA-1): A new prognostic biomarker in HCV infection Margaret Bassendine Received Received
  THU-222 The application of novel HBV pgRNA assay to predict HBeAg clearance on long-term nucleos(t)ide analogues Daryl Lau Received Received
  SAT-223 AA genotype of the deSNP rs6726639 of gene MERTK (MER Tyrosine Kinase) is associated with development of hepatocellular carcinoma after hepatitis C virus clearance Vincenza Calvaruso Received Received
  SAT-224 Design and validation of a risk prediction model for hepatocellular carcinoma development after sustained virological response in chronic hepatitis C patients Ho Soo Chun Received Received
  FRI-224 Reaching out to the undiagnosed people with hepatitis C infection in Belgium: A pilot study Dana Busschots Received Received
  THU-225 Risk prediction model for hepatocellular carcinoma after hepatitis b e antigen seroclearance in patients treated with entecavir or tenofovir Tae Seop Lim Received Received
  SAT-225 The risk of hepatic decompensation is reduced, but not abolished after direct-acting antivirals: The role of portal hypertension Elton Dajti Received Received
  THU-226 Concomitant diabetes mellitus increases risk of liver fibrosis in treatment-naive chronic hepatitis B with low viral loads: Results from a matched case-control study Hei Chun Justin Ma Received Received
  SAT-227 Clinical but not genetic variables predict the development of hepatocellular carcinoma in hepatitis C cirrhotic patients treated with direct-acting antivirals: A 3-year study in 509 patients Elisabetta Degasperi Received Received
  FRI-227 Interleukin-6 -174G/C genotype and interleukin-10 ATA haplotype are associated with clinical comorbidities in chronic hepatitis C patients Luciana Diniz Silva Received Received
  THU-227 NTCP S267F variant associates with decreased susceptibility to HBV infection and decelerated progression of related liver diseases Thanh Binh Mai Received Received
  SAT-228 Sustained virologic response induced by direct-acting antivirals suppresses skeletal muscle loss in patients with type C liver disease Kei Endo Received Received
  SAT-229 Risk of hepatocellular carcinoma in patients with chronic hepatitis C and stage-3 liver fibrosis after sustained virological response with direct acting antivirals Maria Sanchez-Azofra Received Received
  SAT-230 HCV re-infection among HIV-infected MSM in New York City Daniel Fierer Received Received
  THU-231 Risk of hepatocellular carcinoma in patients with immune-tolerant chronic hepatitis B Gyeol Seong Received Received
  FRI-232 An outpatient endoscopy-based patient navigator model improves hepatitis C virus screening among high risk patients: A 3-year prospective observational study among a safety-net health system Grishma Hirode Received Received
  SAT-232 Reinfection following successful HCV DAA therapy among people with recent injecting drug use Jason Grebely Received Received
  THU-232 Hepatitis B vaccination is effective among HIV-infected adults in Uganda Emmanuel Seremba Received Received
  FRI-234 Viral interference between dengue virus and hepatitis C virus infections Jee-Fu Huang Received Received
  FRI-235 Hepatitis C virus risk factors and test uptake in an English prison Kathryn Jack Received Received
  SAT-236 Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals Chung-Feng Huang Received Received
  THU-237 Increasing prevalence of indications to choose bone/renal-friendly antiviral drug: A territory-wide study of 135,414 patients from 2000 to 2017 Grace Wong Received Received
  SAT-237 Histological improvement of hepatitis C virus patients after achieving sustained virological response with direct-acting antivirals Rui Huang Received Received
  THU-238 Low rates of antiviral therapy among treatment-eligible adults with chronic hepatitis B virus infection Robert Wong Received Received
  THU-239 Improving patient knowledge about hepatitis B virus leads to improvements in HBV disease monitoring Robert Wong Received Received
  FRI-240 Comparison of Abbott RealTime HCV genotype II, Abbott HCV genotype plus RUO with Roche Cobas HCV genotyping assays for hepatitis C virus genotyping Chen-Hua Liu Received Received
  SAT-240 Metabolic liver function improves 12 weeks after successful sofosbuvir-based direct-acting antiviral therapy in patients with chronic hepatitis C and advanced liver disease Tea Lund Laursen Received Received
  SAT-241 The dynamics of two plasma markers of type III collagen formation and degradation in the course of chronic hepatitis C viral clearance with direct-acting antiviral therapy Tea Lund Laursen Received Received
  THU-241 Influence of HBV genotype on the risk of hepatocellular carcinoma: mediating roles of different phase of viral infection and epigenetic modifications Wan-Jung Wu Received Received
  FRI-242 Absence of hepatitis C infection despite high-risk sexual behavior in a cohort of men who have sex with men screened in the community: preliminary results of SEXCHECK study Pietro Malosso Received Received
  SAT-242 Liver stiffness measurement is not a predictive factor of HCC in HCV patients with severe fibrosis who achieved SVR by DAA Aline Le Cleach Received Received
  THU-242 Clinical non-invasive markers for hepatic inflammation and fibrosis assessment in chronic hepatitis B with normal alanine aminotransferase Zhao Wu Received Received
  SAT-245 Prospective evaluation of the impact of hepatitis C cure on sexual dysfunction Zoe Mariño Received Received
  SAT-246 Overall survival and incidence of liver-related events in a cohort of cirrhotic patients treated with direct antiviral agents: Results from a multicenter study Chiara Masetti Received Received
  FRI-249 HCV in french prisoner, the study 2017: Fewer patients but more treatment than in 2015 André-Jean Remy Received Received
  FRI-250 Test to cure: Increase outreach linkage to care by use of real time HCV viral load André-Jean Remy Received Received
  SAT-251 The association of serum IFN-?3 levels with liver fibrosis and hepatocarcinogenesis in chronic hepatitis C patients treated with direct-acting antiviral agents Miyako Murakawa Received Received
  THU-251 Metabolic risk factors for advanced liver disease among alcohol risk users in the general population Fredrik berg Received Received
  SAT-252 Long-term effect of direct-acting antivirals therapy in patients with hepatitis C-related decompensated cirrhosis: Russian single academic center experience Ekaterina Nabatchikova Received Received
  SAT-253 Impact of HCV clearance on HCC development and patient survival: Propensity score-matched analysis of an ongoing database of 2173 CHC patients Mina Nakagawa Received Received
  THU-253 Equal efficacy of gastric and jejunal tube feeding in liver cirrhosis and/or alcoholic hepatitis: A randomised controlled trial Palle Bager Received Received
  FRI-253 Changing epidemiology of hepatitis C: A Hospital-level study Joana Roseira Received Received
  SAT-254 Incidence of hepatocellular carcinoma and mortality after HCV elimination by all-oral DAA therapy: Results from a large-scale, multicenter cohort study Eiichi Ogawa Received Received
  THU-254 Cumulative effects of WESTERN DIET and ALCOHOL abuse: A novel MODEL of ASH/NASH-derived liver injury Raquel Benedé Received Received
  THU-255 Long term outcomes of alcoholic patients without clinical evidence of liver disease: A 15 years follow-up study Sonia Bernardo Received Received
  FRI-256 Procoagulant imbalance in chronic hepatitis C and its relationship with cardiovascular and liver damage Giordano Sigon Received Received
  SAT-258 Indocyanine green retention test predicts the risk of portal hypertension-related events after direct-acting antiviral therapy in compensated advanced chronic liver disease patients Federico Ravaioli Received Received
  SAT-259 Achieving accelerated elimination of hepatitis C virus infection by 2025: A case study in France Yuri Sanchez Received Received
  THU-259 The gene signature-MELD score and alcohol consumption determine long-term prognosis of patients with severe alcoholic hepatitis Pierre Deltenre Received Received
  THU-260 Alcoholic cirrhosis is associated with higher in-patient mortality compared to non-alcoholic cirrhosis Xiaowen Fan Received Received
  SAT-261 Elevated HCV reinfection rates after cure on spontaneous clearance among HIV-infected and uninfected men who have sex with men Carmine Rossi Received Received
  FRI-261 Large-scale screening is not useful to identify individuals with hepatitis B or C virus infection: Final results of a Swiss prospective study Aicha Djebali-Trabelsi Received Received
  THU-261 Validation of the pre-treatment neutrophil-to-lymphocyte ratio to predict response to corticosteroids in severe alcoholic hepatitis Ewan Forrest Received Received
  THU-262 A modified Glasgow alcoholic hepatitis score incorporating the neutrophil-to-lymphocyte ratio is superior to other baseline scores of prognosis in alcoholic hepatitis Ewan Forrest Received Received
  SAT-263 Immediate versus delayed hepatitis C treatment is cost-saving in the United Kingdom: A pan-genotypic cost-effectiveness analysis Yuri Sanchez Gonzalez Received Received
  SAT-264 Prediction of hepatocellular carcinoma development using liver stiffness after sustained virological responses by magnetic resonance elastography in patients with chronic hepatitis C Nobuharu Tamaki Received Received
  SAT-265 Anti-VHC therapy does not increase de risk of developing splanchnic vein thrombosis in patients with cirrhosis Fanny Turon Received Received
  SAT-266 High rates of early HCV reinfections after DAA therapy in active intravenous drug users attended at mobile harm reduction units Jorge Valencia Received Received
  THU-267 the increasing burden of alcohol related liver disease: A single tertiary centre experience Arif Hussenbux Received Received
  SAT-268 Noninvasive prediction of gastroesophageal varies by serum wisteria floribunda agglutinin positive Mac-2 binding protein and FIB-4 index in chronic hepatitis C Keiya Watakabe Received Received
  FRI-268 Microbiota signature differs significantly between NAFLD and healthy controls but not between NAFL and NASH Mnevver Demir Received Received
  SAT-271 Genetic risk factors for advanced alcoholic and non-alcoholic liver disease in the general population Fredrik berg Received Received
  FRI-271 Rifaximin alleviates endotoxemia with improved intestinal hyperpermeability with partially modified fecal microbiota in cirrhotic patients Kosuke Kaji Received Received
  SAT-272 A simple algorithm based on electronic medical records to identify NAFLD with advanced fibrosis in patients with Type 2 diabetes Naim Alkhouri Received Received
  FRI-273 Intestinal microbiota signature related to hbeag seroconversion after oral antiviral therapy Jin-Shui Pan Received Received
  THU-273 Role of PNPLA3 rs738409 and MBOAT7 rs626283 during alcohol detoxification: Indication of different mechanisms for fibrosis development Vanessa Rausch Received Received
  FRI-274 Exercise modulates gut microbiota and intestinal barrier functionality counteracting early obesity and NAFLD in an in vivo model David Porras Received Received
  FRI-276 Effect of korean red ginseng on non-alcohlic steatohepatitis: Randomized controlled trial Ki Tae Suk Received Received
  FRI-277 Effect of probiotics in the treatment of NASH: A randomized clinical trial Gabriela Zanatta Port Received Received
  SAT-277 Screening diabetic patients at risk for complications of non-alcoholic fatty liver disease: Prospective evaluation of national and international guideline recommendations Valentin Blank Received Received
  SAT-279 Comparison of different and new types of non-invasive fibrosis tests in NAFLD Paul Cales Received Received
  THU-281 Single nucleotide polymorphisms associated with no interferon lambda 4 production are associated with reduced mortality in alcoholic hepatitis Sidsel Sty Received Received
  THU-282 Augument of liver regeneration protects against ethanol-induced acute liver injury by promoting autophagy YUAN Wu Received Received
  FRI-285 The benchmarks obeticholic acid and elafibranor show variable effects on NASH and hepatic fibrosis in diet-induced or chemically-induced animal models FRANCOIS BRIAND Received Received
  SAT-286 Application of guidelines for fatty liver in two prospective cohorts of human immunodeficiency virus positive patients Sila Cocciolillo Received Received
  SAT-287 A novel non-invasive index based on extracellular matrix markers can identify NAFLD patients with active disease and significant fibrosis: analysis of the CENTAUR study Samuel Daniels Received Received
  SAT-288 Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease Victor de Ledinghen Received Received
  SAT-289 Follow-up of NAFLD/NASH progression using an automated histological image analysis Maxime De Rudder Received Received
  FRI-290 The role of bile acids profile and insulin reistance for the prediction of gallstone disease in a prospective cohort of blood donors Elton Dajti Received Received
  THU-291 Is non-alcoholic fatty liver disease a risk factor for chronic kidney disease? Takemi Akahane Received Received
  THU-292 The natural history of NASH-induced advanced fibrosis in a large cohort of patients with type-2 diabetes Naim Alkhouri Received Received
  FRI-294 Mitochondrial GNMT-complex II is recovered by miR-873-5p targeting in NAFLD David Fernández Ramos Received Received
  THU-294 Non-invasive measures of liver fibrosis in NAFLD is associated with cardiovascular risk Sebastian Bachmayer Received Received
  SAT-294 Automated quantitation of steatosis, inflammation, ballooning and fibrosis using machine learning in routine histological images of liver biopsies of patients with NAFLD Roberta Forlano Received Received
  FRI-295 Advanced glycation end products (AGEs) exacerbate NAFLD progression to liver fibrosis via receptor for AGEs (RAGE) in high fat fed mice Hettya Kandage Dinali Helan Fernando Received Received
  FRI-296 Interaction between the soluble guanylate cyclase and the NLRP3 inflammasome in Kupffer cells: Implications for the anti-inflammatory actions of sGC stimulation in liver Roger Flores-Costa Received Received
  FRI-297 Trans-signaling blockade induces mature-onset obesity and insulin resistance in mice via suppression of PPARalpha Eithan Galun Prof. Received Received
  SAT-297 Prediction of incident severe liver disease in the general population using non-invasive scoring systems Hannes Hagstrm Received Received
  THU-298 Clinical characteristics of NAFLD/NASH patients from gastroenterology and endocrinology clinics Rachel Botchlett Received Received
  FRI-298 Hypoxia-inducible factor 2 alpha drives lipid accumulation in human hepatocytes through the fatty acid translocase CD36 Carmelo García-Monzón Received Received
  THU-300 Prevalence of NAFLD in patients with a first episode of stroke and impact on the mortality and severity at 3 months Teresa Broquetas Received Received
  SAT-301 The FibroScan-based FAST score combining liver stiffness, controlled attenuation parameter and AST can efficiently screen for presence of at risk fibrotic NASH: Evaluation in an American cohort of patients screened for NAFLD Céline Fournier Received Received
  THU-302 Association between advanced fibrosis in fatty liver disease and overall mortality in terms of body size and body fat distribution Goh Eun Chung Received Received
  FRI-304 Elafibranor and pioglitazone reduce NASH and fibrosis in a genetically-obese dietary-induced NASH mouse model Katie Headland Received Received
  FRI-305 Long acting GLP-1/Glucagon co-agonist ameliorates steatosis, inflammation and fibrogenesis in a rodent model of NASH Dorte Holst Received Received
  THU-306 Liver function tests in NAFLD: Changes in upper normal limits, does it really matter? Roberta Forlano Received Received
  SAT-306 Autotaxin is a valuable biomarker for predicting liver fibrosis in patients with non-alcoholic fatty liver disease Yasushi Honda Received Received
  SAT-308 The optimal cut-off points of FIB-4 index for predicting the incidences of HCC and extra-hepatic malignancies in biopsy-proven Japanese NAFLD patients Takanori Ito Received Received
  SAT-309 Prevalence of NAFLD and metabolic syndrome in rural and regional Victoria, Australia William Kemp Received Received
  THU-310 Non-alcoholic steatohepatitis is associated with a higher risk of advanced colorectal neoplasm Jimin Han Received Received
  SAT-310 Real-world evaluation of NASH in US clinical practice: Underutilization of liver biopsy and liver imaging NICOLE WICK Received Received
  SAT-311 The PDGFR-beta containing PRTA-score is a novel non-invasive diagnostic algorithm for significant liver fibrosis in patients with viral, alcoholic, and metabolic liver disease Joeri Lambrecht Received Received
  FRI-313 A novel farnesoid X receptor agonist, TERN-101, reduces liver steatosis, inflammation, ballooning and fibrosis in a murine model of non-alcoholic steatohepatitis Kevin Klucher Received Received
  SAT-313 Exosomal miRNA analysis for classifying severity of disease in biopsy-proven NAFLD patients Young-Sun Lee Received Received
  FRI-314 A novel semicarbazide-sensitive amine oxidase inhibitor, TERN-201, reduces NAS and fibrosis in rodent models of non-alcoholic steatohepatitis Kevin Klucher Received Received
  THU-314 Serum Zinc levels as a prognostic factor for extra-hepatic carcinogenesis in Japanese patients with non-alcoholic liver disease Takanori Ito Received Received
  FRI-315 Lipoprotein lipase deficiency in myeloid cells aggravates the progression of non-alcoholic steatohepatitis Anja Koop Received Received
  FRI-317 Progression of fatty liver disease to steatohepatitis and liver fibrosis is associated with altered Oncostatin M type I and type II receptor expression Philipp Lederer Received Received
  SAT-317 Fibroscan as a tool to improve cardiovascular disease stratification: Truth or myth? Rui Magalhaes Received Received
  SAT-318 Comparative accuracy of NAFLD fibrosis score, apri score, and FIB-4 score in predicting significant fibrosis in African Americans and Caucasians with non-alcoholic fatty liver disease Hemnishil Marella Received Received
  THU-318 Elevated urinary bisphenol A levels are associated with nonalcoholic fatty liver disease among adults in the United States Donghee Kim Received Received
  THU-319 Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis Saekyung Joo Received Received
  FRI-320 TM6SF2 silencing impairs lipid metabolism and trafficking in HepG2 cells carrying the I148M PNPLA3 variant and MBOAT7 deletion Miriam Longo Received Received
  FRI-321 Hepatocyte expression of the protein kinase ERK5 regulates insulin sensitivity Giulia Lori Received Received
  THU-321 Fluorodeoxyglucose perfusion and uptake in abdominal organs is associated with hepatic disease state in patients with non-alcoholic fatty liver disease Alexander Kuo Received Received
  THU-322 Statin use on development and progression of nonalcoholic fatty liver disease: A nationwide cohort study Jung Il Lee Received Received
  SAT-323 Selenoprotein P levels discriminate the degree of hepatic steatosis and are related to the NAS score in patients with non-alcoholic fatty liver disease Chiara Rosso Received Received
  SAT-324 Sonic hedgehog immunohistochemistry is a tissue biomarker of ballooned hepatocytes Michael Schild Received Received
  FRI-325 rs641738 CT variant near MBOAT7-TMC4 increases risk of fibrosis, NASH, and HCC: A meta-analysis Jake Mann Received Received
  THU-326 Relative fat mass: A new definition of obesity and NAFLD Mariana Machado Received Received
  FRI-326 Preclinical evaluation of endothelial dysfunction by peripheral artery tonometry and its correlations with untargeted metabolomic profiles Mario Masarone Received Received
  THU-327 Lifestyle modification leads to a significant decline in aminotrasnsferase activity even without weight reduction in children with non-alcoholic fatty liver disease Anna Mania Received Received
  SAT-328 Controlled attenuation parameter for evaluating liver steatosis in type 2 diabetes patients Ioan Sporea Received Received
  SAT-329 Ethyl glucuronide inhair uncovers a high rate of harmful alcohol consumption in patients with presumed NAFLD Katharina Staufer Received Received
  SAT-330 Whole metabolome profiling identifiesthe combination of an eicosanoid, a bile acid and an androgen as a highly accurate marker of liver fibrosis in patients with non-alcoholic fatty liver disease Felix Stickel Received Received
  THU-330 Biochemical liver tests reflect the genetic risk for fatty liver disease with increasing body weight but not with alcohol consumption Elena Mueller Received Received
  THU-331 Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease: The importance of an elevated mean platelet volume Benjamin H. Mullish Received Received
  FRI-331 Do N1-methylnicotinamide and nicotinamaide administration defferentially alleviated hepatic steatosis? Makoto Nakamuta Received Received
  FRI-332 Effect of combined farnesoid X receptor agonist and angiotensin 2 receptor blocker on established liver fibrosis in rats Tadashi Namisaki Received Received
  THU-334 PNPLA3 rs738409 CG variant predicts liver-related events and death in non-alcoholic fatty liver Salvatore Petta Received Received
  THU-335 FXR rs35724 CG variant modulates cholesterol levels, carotid atherosclerosis and liver damage in non-alcoholic fatty liver Salvatore Petta Received Received
  FRI-336 Lack of CCL2 limits the development of HCC in a model of obesity-associated carcinogenesis Benedetta Piombanti Received Received
  THU-336 Possible ways of concomitant hypothyroidism effect on the course of nonalcoholic fatty liver disease Vasyl Prysyazhnyuk Received Received
  SAT-337 Evaluation of anti-fibrotic properties of OCA and INT-767 in an in vitro system of NAFLD Beatrice Anfuso Received Received
  THU-339 The relationship between the PNPLA3, TLL1 polymorphism combination and advanced fibrosis in Japanese patients with non-alcoholic fatty liver disease Yuya Seko Received Received
  FRI-340 In vivo effects of a novel inhibitor of apoptosis signal-regulating kinase 1 in mouse models of liver injury and metabolic disease Manuel Roqueta-Rivera Received Received
  SAT-341 MET409, an optimized sustained FXR agonist, was safe and well-tolerated in a 14-day phase 1 study in healthy subjects Hubert Chen Received Received
  FRI-342 Combining probiotics and an angiotensin-2 type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis Yasuhiko Sawada Received Received
  SAT-343 Alagebrium ameliorates NAFLD progression in mice fed a high advanced glycation end products diet via direct inhibition of Kupffer cells and indirect inhibition of hepatic stellate cell activation Hettya Kandage Dinali Helan Fernando Received Received
  THU-343 Systematic review: Patient reported quality of life outcomes in non-alcoholic fatty liver disease: Effect of disease severity and duration Humaira Ud-Din Received Received
  SAT-344 MSDC-0602K targets the mitochondrial pyruvate carrier to treat non-alcoholic steatohepatitis BRIAN FINCK Received Received
  THU-344 The influence of non-alcoholic fatty liver disease on a two year prognosis of the patients with stable coronary heart disease depending on SYNTAX score II Iryna Vakalyuk Received Received
  THU-346 Plasma ApoE levels are associated with non-alcoholic fatty liver disease: the PREVEND cohort study Eline H. Wouters-Van Den Berg Received Received
  SAT-347 MRI-PDFF response in MGL-3196 and placebo treated patients predicts reduction in ballooning and inflammation components of NAS and NASH resolution in a 36-week serial liver biopsy study Stephen Harrison Received Received
  SAT-348 Low frequencies of lifestyle interventions and liver-specific medications in a multicentric prospective real world NAFLD cohort: The fatty liver assessment in Germany (FLAG) study Wolf Peter Hofmann Received Received
  SAT-349 Improvement of hepatic inflammation and fibrosis independently of weight loss from a short, individualized, web-based exercise program in patients with NAFLD Yvonne Huber Received Received
  SAT-350 YH25724, a novel long-acting GLP-1/FGF21 dual agonist, exhibits marked anti-fibrotic effects in different experimental models of liver fibrosis Junhwan Kim Received Received
  SAT-355 Fatty liver trends in Southern Italy: Mediterranean or Americanized lifestyle habits? Emilio Molina Molina Received Received
  SAT-356 Anti-metabolic, anti-inflammatory and anti-fibrotic properties of ART-648, a novel phosphodiesterase 4 inhibitor as a potential clinical candidate for non-alcoholic steatohepatitis Hiroshi Nagabukuro Received Received
  SAT-357 Tropifexor, a farnesoid X receptor agonist for the treatment of nonalcoholic steatohepatitis: Interim results based on baseline body mass index from first two parts of Phase 2b study FLIGHT-FXR Arun Sanyal Received Received
  FRI-357 Fibrinogen-like protein 2 aggravates non-alcoholic steatohepatitis by enhancing inflammatory signaling in macrophages Xiaojing Wang Received Received
  SAT-358 Sodium glucose cotransporter 2 inhibitor, canagliflozin ameliorate liver function in Japanese patients with type 2 diabetes mellitus: Subgroup analyses of clinical trials Yuya Seko Received Received
  FRI-358 Differentiation of glucagon and glucagon-like peptide-1 effects on hepatocytes Xiaozhen Wang Received Received
  FRI-360 The role of Paneth cells in the pathogenesis of non-alcoholic fatty liver disease: A potential gut microbiota-associated mechanism Saisai Zhang Received Received
  FRI-362 Exercise training for liver transplant candidates Bandar Aljudaibi Received Received
  THU-363 Lipid nanoparticle pre-treatment improves adeno-associated virus diffusion in the primate liver and enables an increase of therapeutic transgene expression Karin Kwikkers Received Received
  FRI-363 Iron metabolism imbalance is associated with increased mortality following orthotopic liver transplantation Edouard Bardou-Jacquet Received Received
  THU-365 Adeno-associated virus-serotype-specific transduction patterns in mice and non-human primates liver tissue: Implications for therapeutic efficacy Anna Majowicz Received Received
  FRI-366 Portal vein thrombosis in patients on the waiting list for liver transplantation: A single center cohort study Xavier Verhelst Received Received
  FRI-367 Pre-liver transplant profile of cardiovascular risk factors and its impact on early post-transplant outcome Claudia Chialà Received Received
  THU-367 Linking diabetic cardiovascular disease with non-alcoholic fatty liver disease through L-carnitine: A hyperpolarized MRS study Dragana Savic Received Received
  THU-368 Multimodal pre-clinical imaging of liver inflammation and fibrosis Anja Schmidt-Christensen Received Received
  FRI-369 The role of adipose tissue in metabolic and cardiovascular complication after liver transplantation Daria DAmbrosio Received Received
  THU-370 Quantification of hepatic metal overload by laser ablation inductively coupled plasma mass spectrometry imaging (LA-ICP-MSI) Ralf Weiskirchen Received Received
  FRI-371 Correlation between classification of circulating tumor cells in peripheral blood and early recurrence in patients with hepatocellular carcinoma after liver transplantation Binsheng Fu Received Received
  SAT-372 High prevalence of anti HLA Class II de novo donor-specific antibodies during rejection after liver transplantation Jordi Colmenero Received Received
  FRI-372 Next generation sequenzing outperforms standard microbiological cultivation for detection of bacteria in the biliary tract in patients with ischemic type biliary lesions and/or anastomotic stricture Bjrn Grobe Received Received
  SAT-373 Peritoneal mucosal-associated invariant T cells functionally differ from their exhausted circulating counterparts in decompensated cirrhosis Oluwatomi Ibidapo-Obe Received Received
  FRI-373 Mismatch in C-locus Eplets between donor and recipient as independent factor of acute T-cell mediated rejection in liver transplantation Sandra Guiral Foz Received Received
  SAT-375 Therapeutic interleukin 4 modulates monocyte dynamics and accelerates repair and regeneration following acute liver injury Ruairi Lynch Received Received
  THU-375 Transcription factor TRIM33 controls liver progenitor cell towards hepatocyte differentiation through synergizing with SMAD2/3 following massive parenchymal loss Tao Lin Received Received
  THU-376 A viral mediated liver repopulation assay without the use of transgenic animals Wei-Yu Lu Received Received
  FRI-377 Survival outcome after liver transplantation in US patients with hepatocellular carcinoma Mohamed Saleh Ismail Received Received
  THU-377 Systemic blood pressure is not associated with hepatic perfusion and metabolic activity by 18F-FDG PET in patients with NAFLD Souvik Sarkar Received Received
  THU-378 Messenger RNA transcriptome profiling reveals a distinct phenotype of human bone marrow mesenchymal stem cell-derived hepatocytes Dongyan Shi Received Received
  FRI-380 Factors and models for predicting posthepatectomy liver failure in patients undergoing hepatic resection for hepatocellular carcinoma So-Hyun Kim Received Received
  THU-380 DLL4 restores damaged liver by protecting hepatocytes and enhancing cholangiocyte differentiation Jun Li Received Received
  SAT-381 TAA-specific CD8 T-cell responses are inefficiently induced in hepatocellular carcinoma Catrin Tauber Received Received
  FRI-383 Role of traditional cardiovascular risk factors in predicting long term survival after liver transplantation Anoop Koshy Received Received
  FRI-384 Early cardiovascular mortality following liver transplantation: 30-year temporal trends from the Australian & New Zealand liver transplant registry Anoop Koshy Received Received
  FRI-385 Use of machine learning algorithms to predict HCC recurrence after liver transplantation: A proof of concept Phillipe Abreu Received Received
  SAT-385 Production and characterization of humanl liver extracellular matrix hydrogels for in vitro culture of distinct human primary liver cell populations Niki Alevra Sarika Received Received
  THU-387 Eliminating viral hepatitis C in Belgium: A mathematical model of the micro-elimination approach Dana Busschots Received Received
  SAT-389 Obeticholic acid reduces matrix metalloproteinases activity via iNOS modulation in hepatic ischemia/reperfusion injury Laura Giuseppina Di Pasqua Received Received
  FRI-389 Impact of coronary artery disease on long term mortality after liver transplantation Samarth Patel Received Received
  FRI-390 Management of dyslipidemia after liver transplantation Samarth Patel Received Received
  SAT-392 Dickkopf-1 from hepatocellular carcinoma cells promotes the angiogenic potential of endothelial cells by activating the VEGFR-2 signaling pathway Bora Jin Received Received
  THU-396 Hepatitis C screening among the population of Georgia within the national elimination program Sophia Surguladze Received Received
  SAT-396 Heat activation of hepatocytes is sufficient to account for post radiofrequency ablation induced tumorigenesis Aurelia Markezana Received Received
  FRI-397 Sepsis is a major risk factor for delirium post liver transplantation Oliver Tavabie Received Received
  FRI-398 Impact of sarcopenia and myosteatosis on post-transplant complications and survival Daniele Tavano Received Received
  SAT-399 The profile on intracellular gangliosides correlates with the malignant phenotype of cholangiocarcinoma cells and modulates cells adhesion Chiara Raggi Received Received
  FRI-399 Impact of a temporary cardiac arrest in a brain dead liver donor on liver transplantation results Elodie Timsit Received Received
  THU-399 First Belgian hepatitis E seroprevalence study shows low stable birth-cohort specific seroprevalence until 2014, with recent 2016-2018 increase in single centre estimates Erwin Ho Received Received
  SAT-400 IL-1 beta-mediated macrophage-hepatocyte crosstalk upregulates hepcidin under physiologic low oxygen levels Ins Silva Received Received
  THU-400 Alanine-aminotransferase and 20-year risk of liver disease, cancer, ischemic heart disease, and diabetes in a Danish general population sample aged 30-49 years Morten Daniel Jensen Received Received
  SAT-401 Necroptosis signaling molecules regulate hepatic stellate cell activation via MLKL oligomerization-cell death independent pathway Sang Bong Ahn Received Received
  FRI-401 Direct-acting antiviral agents are not associated with an increased risk of hepatocellular carcinoma recurrence in liver transplant recipients with hepatitis C Chung Sang Tse Received Received
  FRI-402 Outcomes after liver transplantation for argininosuccinate lyase deficiency: A longitudinal study Nipun Verma Received Received
  THU-403 The consensus hepatitis C cascade of care: Methodology and initial findings from three countries Jeffrey V Lazarus Received Received
  FRI-403 Impact on post liver transplant outcomes of response to treatment with terlipressin and albumin in patients with hepatorenal syndrome Elia Vettore Received Received
  SAT-403 Polycyclic aromatic hydrocarbons can trigger a hepatocyte release of cytotoxic extracellular vesicles Nettie Van Meteren Received Received
  SAT-404 Discordant NS5a but not NS3 RASs profile in liver and plasma compartments of HIV/HCV genotype 1a/4d infected patients Giulia Morsica Received Received
  FRI-404 Multicenter experience evaluating outcomes of HCV-seropositive donors to HCV-seronegative recipients liver transplantation Karn Wijarnpreecha Received Received
  SAT-405 Genomic expression in circulating PBMCs of patients with hepatocellular carcinoma: Effect of ablative treatment Palmieri Vincenzo Received Received
  FRI-408 Self-stigma among patients with hepatitis B and C and its association with delayed diagnosis and treatment Shireen Abu Elhija Received Received
  SAT-409 Hepatic vein arrival time assessed by contrast-enhanced ultrasound in the non-invasive evaluation of portal hypertension Irene Andaluz García Received Received
  FRI-409 Measuring the impact of a new liver specialist nursing service on patient care Dianne Backhouse Received Received
  FRI-410 Health literacy in outpatients with liver cirrhosis Palle Bager Received Received
  FRI-411 Nurse-led out-patient-clinic for patients with cirrhosis Hanne Bennick Received Received
  SAT-411 Clinical comparison and conversion of international normalized ratio and prothrombin index Paul Cales Received Received
  FRI-412 A collaborative approach to increase access to hepatitis C treatment for the homeless population in Cornwall Helen Hampton Received Received
  SAT-413 Selected cytokines associated with chronic hepatitis b histological activity and fibrosis: A 78-week prospective study Xiao-Qin Dong Received Received
  FRI-415 People are scared: what they dont know dont hurt them. A qualitative exploration of reasons for low uptake of hepatitis C virus testing in an English prison Kathryn Jack Received Received
  THU-416 Use of telemedicine as a cost-effective program to achieve microelimination of hepatitis C virus infection among patients in a public healt care system in a low-income country JOSE LUIS PEREZ HERNANDEZ Received Received
  FRI-416 Assessment of written patient information pertaining to cirrhosis and its complications: A pilot study Lea Ladegaard Grnkjr Received Received
  SAT-416 Transient elastography in normal pregnancies: A prospective cohort study Hannes Hagstrm Received Received
  SAT-418 Splenic stiffness measurement using the ultrasound-fusion method Masashi Hirooka Received Received
  SAT-419 Endotrophin, a fragment of collagen type VI formation (PRO-C6) is associated with progression free survival and mortality in patients with hepatocellular carcinoma Signe Holm Nielsen Received Received
  FRI-419 Is a lack of patient awareness holding back self-management of NAFLD? Bronwen Williams Received Received
  FRI-420 A nurse-led advice and lifestyle intervention shows high levels of patient-reported satisfaction and motivation in community-based management of NAFLD Bronwen Williams Received Received
  SAT-421 A novel score to patients for treatment in chronic hepatitis B: Results from a large Ethiopian cohort Asgeir Johannessen Received Received
  THU-422 Referral, treatment uptake and self-reported barriers in drug users diagnosed with active hepatitis C attending a low-threshold methadone program in Lisbon Mario Jorge Silva Received Received
  FRI-422 Genetic and pathophysiological factors leading to deficient acyl-CoA oxidase 2 (ACOX2) activity in hepatocytes, an alteration which causes oxidative and endoplasmic reticulum stress in liver cells Marta Alonso-Peña Received Received
  THU-423 Patient group monitoring of implementation of WHO viral hepatitis C recommendations: Identifying the gaps between policy and practice in Europe Adam Palayew Received Received
  FRI-423 Role of antithrombin deficiency in splanchnic vein thrombosis Anna Baiges Received Received
  FRI-424 Estrogen-containing oral contraceptives are associated with polycystic liver disease severity in pre-menopausal patients Lucas H.P. Bernts Received Received
  SAT-425 Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis Rocio Macias Received Received
  SAT-427 The role of liver and spleen stiffness measurement in predicting hepatic decompensation after HCV eradication with direct antiviral agents therapy Federico Ravaioli Received Received
  THU-428 Routine point of care antenatal screening of hepatitis B virus in windhoek, Namibia: Feasibility of implementation Cynthia Tamandjou Received Received
  FRI-428 Prevalence and impact of sarcopenia in non-cirrhotic portal hypertension Simone Di Cola Received Received
  FRI-429 Impact of allelic variants of platelet receptors and coagulation system genes in the development of clinical manifestations of Wilsons desease Saglara Fastovets Received Received
  THU-429 Serial testing with the enhanced liver fibrosis test and liver stiffness is cost-effective for detection of advanced alcoholic liver disease in primary care Maja Thiele Received Received
  THU-430 Changing prevalence of aetiological factors among Australians hospitalized for cirrhosis Patricia Valery Received Received
  THU-431 The burgeoning growth in cirrhosis-related hospitalization in Australia, 2008-2016 Patricia Valery Received Received
  FRI-431 Clinical spectrum of congenital hepatic fibrosis in children: 15 year experience from a tertiary care centre in north India Vybhav Gummadi Received Received
  THU-432 Viral sustained response in chronic hepatitis C did not reduce short term heatlh expediture Mercedes Vergara Gómez Received Received
  THU-433 Availability of information in drug labels for appropriate prescribing in patients with hepatic impairment Rianne Weersink Received Received
  SAT-433 Portal venous velocity and platelet count as a simple non invasive tool to rule out the presence of varices needing treatment in patients with compensated cirrhosis Francesco Santopaolo Received Received
  SAT-434 Liver stiffness measurement by transient elastography for the prognosis of hepatic carcinoma, decompensation, and death in patients with chronic liver diseases: A systematic review and meta analysis Yue Shen Received Received
  THU-434 Poorly chosen upper limits of normal for alanine aminotransferase may burden the patient and health system unnecessarily Johannes Wiegand Received Received
  FRI-434 Role of next generation sequencing in the etiological diagnosis of splanchnic venous thrombosis Marta Magaz Received Received
  FRI-435 Progression to cirrhosis is not infrequent in patients with Wilsons disease despite treatment Zoe Mariño Received Received
  SAT-435 Quantitative MRCP imaging (MRCP): Accuracy, repeatability and reproducibility evaluation in healthy and liver disease patients gary woodward Received Received
  SAT-436 Inhibition of autophagy prolongs recipient survival through accelerating CD8 T-cell apoptosis in a rat liver transplantation model Xiaolong Chen Received Received
  FRI-438 Histone deacetylase 5 methylation changes in mice and patients with Wilson disease Valentina Medici Received Received
  SAT-439 Identification of new drug targets to prevent ischemia-induced bile toxicity using a human biliary organoid model Floris Roos Received Received
  THU-440 Changing incidence of reported hepatitis B and its different trends amongest age groups in china from 2004-2016 Mingyuan Zhang Received Received
  FRI-441 A novel heterozygous ABCB4, RUNDC3B and ABCB1 deletion associated with severe cholestatic liver disease in adults Benedetta Terziroli Beretta-Piccoli Received Received
  THU-442 Role of drug transporters in the chemoresistance of hepatoblastoma Maitane Asensio Received Received
  FRI-447 Clinical characteristics of liver cirrhosis and hepatocellular carcinoma occuring after Fontan operation Jun Sik Yoon Received Received
  FRI-451 Transarterial chemoembolization versus best supportive care for patients with hepatocellular carcinoma with portal vein tumour thrombus Xiao Xiang Received Received
  SAT-452 Analysis of intrahepatic sarcomatoid cholangiocarcinoma compared with intrahepatic adenocarcinoma Yanghyon Baek Received Received
  THU-452 TFOX, a novel TGF-beta target gene, switches TGF-beta activity toward EMT during tumor progression of human hepatocellular carcinoma Cedric Coulouarn Received Received
  THU-453 Dissecting the landscape of (epi-)genetic alterations during sequential evolution of liver cancer Carolin Czauderna Received Received
  SAT-453 Effects of sorafenib on pancreatic volume and their clinical implications in patients with hepatocellular carcinoma LUCA IELASI Received Received
  THU-454 Dual CCR2/CCR5 antagonism as macrophage targeted therapy in experimental hepatocellular carcinoma Helena Degroote Received Received
  THU-455 Metabolomic analysis by 1H-nuclear magnetic resonance spectroscopy suggest that there are 2 phenotypes of human hepatocellular carcinoma developed in non-alcoholic fatty liver disease according to fibrosis level (F0F1 vs F3F4) Aicha Demidem Received Received
  FRI-455 Effect of huaier granule on recurrence after curative resection of HCC: A multicenter, randomized clinical trial Qian Chen Received Received
  FRI-456 MELD score is the only predictor for 30-day mortality in patients with ruptured hepatocellular carcinoma treated by emergent transarterial embolization Ya-Ting Cheng Received Received
  FRI-457 Comparative long-term outcomes of laparoscopic liver resection and radio frequency ablation for hepatocellular carcinoma: Location of tumor matters Jai Young Cho Received Received
  SAT-457 Sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure Tsung-Yi Cheng Received Received
  SAT-458 Subtraction arterial images of hepatocyte-specific contrast-enhanced MRI: Added value for the diagnosis of hepatocellular carcinoma in the liver imaging reporting and data system v2018 Sang Hyun Choi Received Received
  THU-458 Identification of relevant oncogenes in RAS-activated primary liver cancer using a targeted screening approach Ursula Ehmer Received Received
  FRI-458 Response evaluation using modified RECIST criteria predict outcomes better than RECIST 1.1 criteria in patients with HCC treated with Yttrium-90 radioembolization Hongjun Choi Received Received
  FRI-459 Prognostic performance of ten non-invasive liver function tests in patients with hepatocellular carcinoma submitted to transarterial chemoembolization Pedro Costa-Moreira Received Received
  SAT-459 NASH as a risk factor for intrahepatic cholangiocarcinoma and its prognostic role: Case-control study Stefania De Lorenzo Received Received
  THU-459 Non-parenchymal TREM2 halts hepatocarcinogenesis through the inhibition of liver inflammation and hepatocyte proliferation Ibone Labiano Received Received
  SAT-460 Influence of sustained virological response in diagnostic performance of alpha-fetoprotein for hepatocellular carcinoma in patients with HCV-cirrhosis Ana Gómez Received Received
  THU-461 A diet-induced lean nonalcoholic steatohepatitis-associated hepatocellular carcinoma mouse model Elizabeth Vlock Received Received
  FRI-461 Thermal ablation is a safe and effective treatment for intrahepatic cholangiocarcinoma in patients with cirrhosis Álvaro Díaz-González Received Received
  SAT-461 HCC recurrence after DAA treatment in HCV patients Maria Guarino Received Received
  THU-462 StARD1 is induced in human HCC and its overexpression aggravates cholesterol-mediated hepatocarcinogenesis in vivo José Fernandez-Checa Received Received
  FRI-462 A multicenter international study of sorafenib treatment in patients with hepatocellular carcinoma and chronic kidney disease undergoing hemodialysis Álvaro Díaz-González Received Received
  FRI-463 Long-term outcomes of irreversible electroporation for hepatocellular carcinoma Elliot Freeman Received Received
  FRI-464 Percutaneous microwave is better than radiofrequency ablation to obtain complete response in cirrhotic patients with very early and early hepatocellular carcinoma Silvia Gaia Received Received
  THU-464 NASH-related liver carcinogenesis is critically affected by hypoxia-inducible factor 2 alpha Beatrice Foglia Received Received
  SAT-465 The NIACE Score: A prognostic indicator in Hepatocellular carcinoma William Kemp Received Received
  THU-465 Variation of different histone deacetylases and the functional effects of HDAC inhibitors in hepatocellular carcinoma Kim Freese Received Received
  FRI-465 The INCRNA H19 is an oncogenic driver of HCC in chronic inflammation-mediated mouse model Lika Gamaev Received Received
  FRI-466 A single centre experience of transarterial radioembolisation using Rhenium 188 for treatment of liver space occupying lesions Jeffey George Received Received
  SAT-466 A meta-analysis of risk factors for intrahepatic and extrahepatic cholangiocarcinoma Shahid Khan Received Received
  THU-468 SLU7 controls genome integrity: New role of truncated SRSF3 proteins Maddalen Jimenez Received Received
  SAT-468 Prognostic value of post-treatment liver stiffness in hepatocellular carinoma with histologically confirmed cirrhosis Jung Il Lee Received Received
  THU-469 Nanoparticular bisphosphonate to ively target and repolarize liver macrophages for efficient anti-tumour response Leonard Kaps Received Received
  FRI-469 Vitamin K dosing could improve anti-cancer outcome of transarterial chemoembolization for patients with hepatocellular carcinoma-an open label, randomized, phase II study Yoshimichi Haruna Received Received
  SAT-470 Circulating levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of cholangiocarcinoma Sven Loosen Received Received
  FRI-470 External beam radiotherapy as an effective and safe treatment in all stages of hepatocellular carcinoma with cirrhotic liver disease : A single institution experience Clémence Hollande Received Received
  THU-470 The mRNA-binding protein tristetraprolin promotes hepatocarcinogenesis but inhibits tumour progression in liver cancer Sonja Kessler Received Received
  FRI-473 Safety and effectiveness of regorafenib in recurrent HCC after liver transplantation and progression on sorafenib: A real-life multicentre study Massimo Iavarone Received Received
  FRI-474 AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma Massimo iavarone Received Received
  SAT-474 Misdiagnosis of focal liver lesions by means of CEUS Tudor-Voicu Moga Received Received
  THU-474 Existence of intratumoral teriary lymphoid structures predicts better prognosis in Barcelona clinic of liver cancer stage 0-a hepatocellular carcinoma Hui Li Received Received
  SAT-475 Clinical validation of the role of contrast-enhanced ultrasound in the EASL guidelines for the diagnosis of hepatocellular carcinoma Lorenzo Mulazzani Received Received
  FRI-475 Experience impacts on reasons leading to sorafenib discontinuation and chance of long-term response Ielasi Luca Received Received
  FRI-476 Repeated surgical resection versus radiofrequency ablation for recurrent hepatocellular carcinoma after surgical resection : A propensity score matching analysis Chang Ke-Bin Received Received
  THU-477 Sumoylation/acetylation drives forward oncogenic role of LKB1 in Liver Fernando Lopitz Otsoa Received Received
  THU-478 CXCL5 induced by transforming growth factor-beta and Axl signalling causes neutrophil extracellular trap formation in hepatocellular carcinoma Wolfgang Mikulits Received Received
  FRI-478 Survival outcomes of TACE in treatment-naive and recurrent HCC after curative resection: A propensity score-matched analysis David Sooik Kim Received Received
  SAT-479 Analysis of the relationship between serum creatinine/cystatin C ratio and muscle mass in patients with hepatocellular carcinoma Hirotaka Oura Received Received
  SAT-480 Long-term survivors in patients with hepatocellular carcinoma: An ITA.LI.CA report Filippo Pelizzaro Received Received
  THU-480 Imaging mechanical stiffness and molecular landscapes of cancer stem cell niches in human hepatocellular carcinomas Orlando Musso Received Received
  SAT-481 Intratumoral mast cell infiltration and recurrence of hepatocellular carcinoma in patients undergoing orthotopic liver transplantation Nataliya Rohr-Udilova Received Received
  THU-482 A human anti-MICA/B antibody boost NK cell responses in hepatocellular carcinoma Barbara Oliviero Received Received
  FRI-482 Ideal number of lymph nodes to harvest for intrahepatic cholangiocarcionoma Sung Hyun kim Received Received
  FRI-483 Endoscopic biliary drainage in patients with cholangiocarcinoma: Polyethylene versus self-expanding metal stents Martha M. Kirstein Received Received
  THU-483 Blood based weighted gene co-expression network analysis identifies miRNA prognostic biomarkers for HCC Devis Pascut Received Received
  THU-484 Mass spectrometric analysis of serum haptoglobin fucolysation in patients stratified according to fibrosis stages, and the presence of hepatocellular carcinoma Valentina Peta Received Received
  SAT-484 CEUS pattern of hepatocellular carcinoma: Prognostic implication Vito Sansone Received Received
  FRI-484 The early clinical response at 2 weeks of lenvatinib therapy for patients with advanced HCC Teiji Kuzuya Received Received
  THU-485 Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma David James Pinato Received Received
  SAT-485 European cholangiocarcinoma (EU-CCA) registry: An initiative to broaden awareness on the second most common primary liver cancer Alvaro Santos-Laso Received Received
  FRI-485 Laparoscopic liver resection vs. Percutaneous radiofrequency ablation for small single nodular HCC: Comparison of treatment outcome Dong Ho Lee Received Received
  SAT-486 Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma Bernhard Scheiner Received Received
  THU-486 A pro-regenerative environment triggers premalignant to malignant transformation and pinpoints new therapeutic targets Anna Potapova Received Received
  FRI-486 Serum cytokines and chemokines correlated with tumor recurrrence and survival after surgical resection for overt and occult HBV-related hepatocellular carcinoma I-Cheng Lee Received Received
  THU-487 Circulating MIR-4492 as a biomarker to predict therapy response and disease free survival in hepatocellular carcinoma Muhammad Yogi Pratama Received Received
  FRI-487 A new prognosis prediction model in patients with hepatocellular carcinoma after Yttrium-90 radioembolization Jae Seung Lee Received Received
  FRI-488 Prognostic value of tumor markers after a complete response to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma following curative resection Jae Seung Lee Received Received
  THU-488 Acquisition of stem-like features in cholangiocarcinoma is associated with an oxidative metabolism Chiara Raggi Received Received
  SAT-488 Both ALBI/delta ALBI grade are good predictive parameters for prognosis in chc/hcc patients with transarterial chemoembolization treatment Wei Teng Received Received
  THU-489 Mixed HCC-ICC liver cancer derives from hepatic progenitor cells: A lineage tracing investigation in a mouse liver inflammation model NOFAR ROSENBERG Received Received
  FRI-489 Downstaging by 90-yttrium radioembolization of unresectable locally advanced hepatocellular carcinoma: A single center experience Carolina Martelletti Received Received
  SAT-489 Efficacy and safety of thermal ablation in patients with hepatocellular carcinoma and high comorbidity Maria Torner Simó Received Received
  FRI-492 Long-term outcome according to initial treatment modality in multiple hepatocellular carcinoma within the Milan criteria Joo Hyun Oh Received Received
  THU-492 Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma Ulrich Spengler Received Received
  FRI-493 Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocelluar carcinoma Takuya Okamoto Received Received
  SAT-494 Global hepatocellular carcinoma mortality trends: An analysis of the world health organization cancer mortality database Robert Wong Received Received
  THU-494 MicroRNA-96 in non-B non-C hepatocellular carcinoma Takeshi Matsui Received Received
  FRI-495 Post transarterial chemoembolization fever can predict poor survival in patients with TNM stage I hepatocellular carcinoma Chien-Wei Peng Received Received
  FRI-496 Recurrence of hepatocellular carcinoma in patients with complete response treated with direct acting antivirals in clinical practice Christie Perello Received Received
  FRI-497 Shifting to sorafenib is beneficial for hepatocellular carcinoma patients with transarterial chemoembolization refractoriness: A real world experience Po-Ting Lin Received Received
  FRI-498 A current status of therapeutic choice and feasibility for hepato cellular carcinoma patients over 70 years old Seoung Yoon Rho Received Received
  THU-499 Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein Yuki Tsuji Received Received
  FRI-500 Sorafenib for recurrent hepatocellular carcinoma after liver transplantation: Intrinsic resistance or not? Vito Sansone Received Received
  THU-501 Myeloid-specific IRE1 alpha deletion reduces tumour development in a non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model Sanne Van Campenhout Received Received
  FRI-505 Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting Takuya Sho Received Received
  FRI-507 Hepatocyte-specific role of c-Jun N-terminal kinase 2 for disease progression and therapy in chronic liver disease Marius Woitok Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:30, Fri 8:30-15:00
02:19
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
Captcha image
 

EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

The International Liver Congress 2019

 

10-14 April 2019 Vienna
HELP LINE
Manage Orders
FAQs

SUBMISSION DEADLINE FOR PRINTING POSTERS: 20 March 2019 at 23:59 GMT+1
SUBMISSION DEADLINE FOR
EPOSTERS: 3 April 2019 at 23:59 GMT+1
 
 

Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 10/04/2019 TO 10/04/2020
Poster
Gallery
Oral Presentation
& Video Gallery
Poster Discussion
Forum
                   DOI: 10.3252/pso.eu.ILC2019.2019 
PrintingOnline
Submit your poster online
in powerpoint format

   Poster submission deadline 20/03/2019
Upload Poster
Upload Oral Presentation of Video
Upload
Poster
Upload Oral
Presentation or Video








PosterSessionOnline
Logo Draft
 
Logo Cert